Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Share (Tables)

Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
EPS Numerator:
Net income (loss)	$	(13,821)	$	(17,576)	$	25,679	$	3,667
EPS Denominator—Basic:
Weighted-average common shares outstanding		170,192		168,570		169,997		168,519
EPS Denominator—Diluted:
Weighted-average common shares outstanding		170,192		168,570		169,997		168,519
Dilutive effect of stock options, restricted stock units and shares under Purchase Plan		—		—		5,915		6
Weighted-average shares outstanding and common stock equivalents		170,192		168,570		175,912		168,525

Net income (loss) per share
Basic	$	(0.08)	$	(0.10)	$	0.15	$	0.02
Diluted	$	(0.08)	$	(0.10)	$	0.15	$	0.02

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Outstanding stock options		30,639		27,598		9,469		26,536
Restricted stock units		234		—		4		—
Purchase Plan		—		344		—		—
Total		30,873		27,942		9,473		26,536